{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:26:10Z","timestamp":1790717170894,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s13555-024-01207-y","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T12:01:37Z","timestamp":1719057697000},"page":"1901-1916","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ustekinumab in Hidradenitis Suppurativa: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"14","author":[{"given":"Rahul","family":"Masson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Seivright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha","family":"Atluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltefat","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Hogeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian Y.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,22]]},"reference":[{"issue":"2","key":"1207_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMcp1014163","volume":"366","author":"GBE Jemec","year":"2012","unstructured":"Jemec GBE. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158\u201364. https:\/\/doi.org\/10.1056\/NEJMcp1014163.","journal-title":"N Engl J Med"},{"issue":"8","key":"1207_CR2","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.3390\/biomedicines10082039","volume":"10","author":"C Moltrasio","year":"2022","unstructured":"Moltrasio C, Tricarico PM, Romagnuolo M, Marzano AV, Crovella S. Hidradenitis suppurativa: a perspective on genetic factors involved in the disease. Biomedicines. 2022;10(8):2039. https:\/\/doi.org\/10.3390\/biomedicines10082039.","journal-title":"Biomedicines"},{"issue":"1","key":"1207_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/genes15010038","volume":"15","author":"EM Nardacchione","year":"2023","unstructured":"Nardacchione EM, Tricarico PM, Moura R, et al. Unraveling the epigenetic tapestry: decoding the impact of epigenetic modifications in hidradenitis suppurativa pathogenesis. Genes. 2023;15(1):38. https:\/\/doi.org\/10.3390\/genes15010038.","journal-title":"Genes"},{"issue":"12","key":"1207_CR4","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/exd.14214","volume":"29","author":"CC Zouboulis","year":"2020","unstructured":"Zouboulis CC, Benhadou F, Byrd AS, et al. What causes hidradenitis suppurativa?\u201415 years after. Exp Dermatol. 2020;29(12):1154\u201370. https:\/\/doi.org\/10.1111\/exd.14214.","journal-title":"Exp Dermatol"},{"issue":"5","key":"1207_CR5","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jaad.2019.08.089","volume":"82","author":"SR Goldburg","year":"2020","unstructured":"Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: current and emerging treatments. J Am Acad Dermatol. 2020;82(5):1061\u201382. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.089.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1207_CR6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2023.2298356","volume":"20","author":"CA Maronese","year":"2024","unstructured":"Maronese CA, Moltrasio C, Genovese G, Marzano AV. Biologics for hidradenitis suppurativa: evolution of the treatment paradigm. Expert Rev Clin Immunol. 2024;20(5):525\u201345. https:\/\/doi.org\/10.1080\/1744666X.2023.2298356.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"1207_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504370.","journal-title":"N Engl J Med"},{"issue":"1","key":"1207_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1080\/09546634.2020.1755008","volume":"33","author":"T Montero-Vilchez","year":"2022","unstructured":"Montero-Vilchez T, Pozo-Rom\u00e1n T, S\u00e1nchez-Velicia L, Vega-Guti\u00e9rrez J, Arias-Santiago S, Molina-Leyva A. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review. J Dermatol Treat. 2022;33(1):348\u201353. https:\/\/doi.org\/10.1080\/09546634.2020.1755008.","journal-title":"J Dermatol Treat"},{"issue":"4","key":"1207_CR9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/bjd.14338","volume":"174","author":"JL Blok","year":"2016","unstructured":"Blok JL, Li K, Brodmerkel C, Horv\u00e1tovich P, Jonkman MF, Horv\u00e1th B. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174(4):839\u201346. https:\/\/doi.org\/10.1111\/bjd.14338.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1207_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.36849\/JDD.6298","volume":"21","author":"A Hollywood","year":"2022","unstructured":"Hollywood A, Murray G, Fleming S, Kirby B, Hughes R. Ustekinumab in the management of hidradenitis suppurativa: a retrospective study. J Drugs Dermatol. 2022;21(3):319\u201320. https:\/\/doi.org\/10.36849\/JDD.6298.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"1207_CR11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/bjd.21066","volume":"187","author":"SW Jiang","year":"2022","unstructured":"Jiang SW, Kwock JT, Liu B, et al. High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa. Br J Dermatol. 2022;187(3):417\u20139. https:\/\/doi.org\/10.1111\/bjd.21066.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1207_CR12","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","volume":"65","author":"C Schlapbach","year":"2011","unstructured":"Schlapbach C, H\u00e4nni T, Yawalkar N, Hunger RE. Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65(4):790\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2010.07.010.","journal-title":"J Am Acad Dermatol"},{"key":"1207_CR13","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1016\/j.cgh.2021.10.002","volume":"20","author":"J Meserve","year":"2021","unstructured":"Meserve J, Ma C, Dulai PS, Jairath V, Singh S. Effectiveness of reinduction and\/or dose escalation of ustekinumab in Crohn\u2019s disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;20:2728-2740.e1. https:\/\/doi.org\/10.1016\/j.cgh.2021.10.002. (Published online October 8).","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"1207_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033486","volume":"7","author":"EA Brezinski","year":"2012","unstructured":"Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS ONE. 2012;7(4): e33486. https:\/\/doi.org\/10.1371\/journal.pone.0033486.","journal-title":"PLoS ONE"},{"issue":"1","key":"1207_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14706","volume":"34","author":"G Nazzaro","year":"2021","unstructured":"Nazzaro G, Calzari P, Passoni E, et al. Vascularization and fibrosis are important ultrasonographic tools for assessing response to adalimumab in hidradenitis suppurativa: prospective study of 32 patients. Dermatol Ther. 2021;34(1): e14706. https:\/\/doi.org\/10.1111\/dth.14706.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1207_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/apt.14834","volume":"48","author":"CR Rowan","year":"2018","unstructured":"Rowan CR, Keegan D, Byrne K, et al. Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study. Aliment Pharmacol Ther. 2018;48(3):333\u20139. https:\/\/doi.org\/10.1111\/apt.14834.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"1207_CR17","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1001\/jamadermatol.2019.1783","volume":"155","author":"T Tsakok","year":"2019","unstructured":"Tsakok T, Wilson N, Dand N, et al. Association of serum ustekinumab levels with clinical response in psoriasis. JAMA Dermatol. 2019;155(11):1235. https:\/\/doi.org\/10.1001\/jamadermatol.2019.1783.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1207_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/bjd.12654","volume":"170","author":"L Hsu","year":"2014","unstructured":"Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014;170(2):261\u201373. https:\/\/doi.org\/10.1111\/bjd.12654.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1207_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamadermatol.2021.4805","volume":"158","author":"HC Ring","year":"2022","unstructured":"Ring HC, Maul JT, Yao Y, et al. Drug survival of biologics in patients with hidradenitis suppurativa. JAMA Dermatol. 2022;158(2):184\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2021.4805.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"1207_CR20","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1093\/ibd\/izaa236","volume":"27","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Feagan BG, Danese S, et al. Safety of ustekinumab in inflammatory Bowel disease: pooled safety analysis of results from phase 2\/3 studies. Inflamm Bowel Dis. 2021;27(7):994\u20131007. https:\/\/doi.org\/10.1093\/ibd\/izaa236.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"1207_CR21","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.cgh.2022.01.013","volume":"20","author":"D Cheng","year":"2022","unstructured":"Cheng D, Kochar BD, Cai T, Ananthakrishnan AN. Risk of infections with ustekinumab and tofacitinib compared to tumor necrosis factor \u03b1 antagonists in inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2022;20(10):2366-2372.e6. https:\/\/doi.org\/10.1016\/j.cgh.2022.01.013.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1207_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000501075","volume":"236","author":"J Roman\u00ed","year":"2020","unstructured":"Roman\u00ed J, Vilarrasa E, Martorell A, Fuertes I, Ciudad C, Molina-Leyva A. Ustekinumab with intravenous infusion: results in hidradenitis suppurativa. Dermatology. 2020;236(1):21\u20134. https:\/\/doi.org\/10.1159\/000501075.","journal-title":"Dermatology"},{"issue":"2","key":"1207_CR23","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1080\/09546634.2020.1776208","volume":"33","author":"S Valenzuela-Ubi\u00f1a","year":"2022","unstructured":"Valenzuela-Ubi\u00f1a S, Jim\u00e9nez-Gallo D, Villegas-Romero I, Rodr\u00edguez-Mateos ME, Linares-Barrios M. Effectiveness of ustekinumab for moderate-to-severe hidradenitis suppurativa: a case series. J Dermatol Treat. 2022;33(2):1159\u201362. https:\/\/doi.org\/10.1080\/09546634.2020.1776208.","journal-title":"J Dermatol Treat"},{"key":"1207_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14054","author":"EM S\u00e1nchez-Mart\u00ednez","year":"2020","unstructured":"S\u00e1nchez-Mart\u00ednez EM, Garc\u00eda-Ruiz R, Moneva-L\u00e9niz LM, Mateu-Puchades A. Effectiveness and safety of ustekinumab in patients with hidradenitis suppurativa using intravenous induction. Dermatol Ther. 2020. https:\/\/doi.org\/10.1111\/dth.14054.","journal-title":"Dermatol Ther"},{"issue":"7","key":"1207_CR25","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.1468-3083.2011.04123.x","volume":"26","author":"WP Gulliver","year":"2012","unstructured":"Gulliver WP, Jemec GBE, Baker KA. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2012;26(7):911\u20134. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04123.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1207_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/jdv.12438","volume":"29","author":"G Martin-Ezquerra","year":"2015","unstructured":"Martin-Ezquerra G, Masferrer E, Masferrer-Niub\u00f2 M, et al. Use of biological treatments in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2015;29(1):56\u201360. https:\/\/doi.org\/10.1111\/jdv.12438.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1207_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1684\/ejd.2019.3663","volume":"29","author":"L Scholl","year":"2019","unstructured":"Scholl L, Hessam S, Garcovich S, Bechara FG. High-dosage ustekinumab for the treatment of severe hidradenitis suppurativa. Eur J Dermatol. 2019;29(6):659\u201361. https:\/\/doi.org\/10.1684\/ejd.2019.3663.","journal-title":"Eur J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01207-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01207-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01207-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T17:19:35Z","timestamp":1721495975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01207-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,22]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1207"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01207-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,22]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jennifer L. Hsiao is on the Board of Directors for the Hidradenitis Suppurativa Foundation and has served as a consultant for AbbVie, Aclaris, Boehringer Ingelheim, and Novartis, as a speaker for AbbVie, and as an investigator for Amgen, Aristea, Boehringer Ingelheim, and Incyte. Jennifer L. Hsiao is an editorial board member of <i>Dermatology and Therapy<\/i>. Jennifer L. Hsiao was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Vivian Y. Shi is on the board of directors for the Hidradenitis Suppurativa Foundation (HSF), is an advisor for the National Eczema Association, is a stock shareholder of Learn Health, and has served as an advisory board member, investigator, or speaker for and\/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Genentech, Eli Lilly, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Boehringer Ingelheim, Almirall,\u00a0Alumis, Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt\u2019s Bees, Galderma, Kiniksa, UCB, Bain Capital, Target-PharmaSolutions, Altus Lab\/cQuell, MYOR, Polyfins Technology, GpSkin, and Skin Actives Scientific. Iltefat Hamzavi has served as a consultant to Abbvie, Pfizer, Incyte,UCB,Boerhinger Ingelheim, Sonoma, Union Therapeutics, Novartis, Jansen, Avita, and Galderma, has been an investigator for Lenicura, Pfizer, Incyte, Avita, and Loreal\/Laroche Posay, and is a board member and past-president of the HS Foundation and Global Vitiligo Foundation. There was no financial transaction for the preparation of this manuscript. All other authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. The databases used in this study are publicly available: MEDLINE:  and Embase: .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}